Allogene retains control of cancer therapy after arbitration ruling
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Oil slips but stays near six-month highs on Saudi attacks
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- Serbia's Vucic concedes defeat to student led movement in parliamentary election
- Stocks, bonds edge up ahead of 'formidable' week for risk
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
December 15, 2025 5:39 PM ESTArbitration Ruling Reaffirms Allogenes Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogenes Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company... More



